A step forward for patients with NRAS-mutant melanoma.
作者信息
Postow Michael A, Chapman Paul B
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Lancet Oncol. 2017 Apr;18(4):414-415. doi: 10.1016/S1470-2045(17)30172-9. Epub 2017 Mar 9.
Abstract
摘要
相似文献
1
A step forward for patients with NRAS-mutant melanoma.NRAS 突变型黑色素瘤患者向前迈进了一步。
Lancet Oncol. 2017 Apr;18(4):414-415. doi: 10.1016/S1470-2045(17)30172-9. Epub 2017 Mar 9.
2
"Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?NRAS 突变型黑色素瘤中的“寻找尼莫”：迈向序贯策略的一步？
Lancet Oncol. 2017 Jun;18(6):e298. doi: 10.1016/S1470-2045(17)30349-2.
3
BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.俄罗斯黑色素瘤患者的BRAF和NRAS突变：一项全国性研究的结果
Melanoma Res. 2016 Oct;26(5):442-7. doi: 10.1097/CMR.0000000000000278.
4
Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.BRAF和NRAS原发性皮肤黑色素瘤的皮肤镜特征：与点状分布及蓝白色薄纱样表现的关联
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e57-e59. doi: 10.1111/jdv.15906. Epub 2019 Sep 11.
5
BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.前瞻性原发性皮肤黑色素瘤系列研究中的BRAF、NRAS和MC1R状态
Br J Dermatol. 2015 Apr;172(4):1128-31. doi: 10.1111/bjd.13521. Epub 2015 Mar 6.
6
BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells.BRAF和NRAS突变在黑色素瘤及单个黑色素瘤细胞中并非相互排斥。
Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):e14-5. doi: 10.1097/PAI.0000000000000217.
7
Targeting Mutations in Advanced Melanoma.针对晚期黑色素瘤中的突变
J Clin Oncol. 2023 May 10;41(14):2661-2664. doi: 10.1200/JCO.23.00205. Epub 2023 Mar 22.
8
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.一项基于临床的转移性黑色素瘤队列中 BRAF 和 NRAS 突变的临床意义。
Br J Dermatol. 2013 Nov;169(5):1049-55. doi: 10.1111/bjd.12504.
9
KIT, NRAS, and BRAF mutations in nail apparatus melanoma.甲襞黑色素瘤中的KIT、NRAS和BRAF突变。
Pigment Cell Melanoma Res. 2013 Sep;26(5):758-60. doi: 10.1111/pcmr.12123. Epub 2013 Jun 20.
10
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.BRAF 和 NRAS 突变在黑色素瘤中的预后意义：一项来自常规护理的德国研究。
BMC Cancer. 2017 Aug 10;17(1):536. doi: 10.1186/s12885-017-3529-5.
引用本文的文献
1
Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.利用 TERT 依赖性作为治疗NRAS 突变型黑色素瘤的策略。
Oncogene. 2018 Jul;37(30):4058-4072. doi: 10.1038/s41388-018-0247-7. Epub 2018 Apr 26.
本文引用的文献
1
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.优化阿贝西利与维莫非尼联合给药策略用于BRAF突变型黑色素瘤异种移植瘤
Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40.
2
Genomic Classification of Cutaneous Melanoma.皮肤黑色素瘤的基因组分类
Cell. 2015 Jun 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044.
3
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.MEK162 治疗携带 NRAS 或 Val600 BRAF 突变的晚期黑色素瘤患者：一项非随机、开放标签的 2 期研究。
Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13.
4
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.在黑色素瘤中建立vemurafenib 耐药模型揭示了一种预防耐药的策略。
Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9.
5
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.致癌性NRAS 信号通路在黑色素瘤中差异调节存活和增殖。
Nat Med. 2012 Oct;18(10):1503-10. doi: 10.1038/nm.2941. Epub 2012 Sep 16.
6
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.RAF 抑制剂 PLX4032 以 V600E BRAF 选择性方式抑制 ERK 信号和肿瘤细胞增殖。
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.
7
Regulation of Raf-1 by direct feedback phosphorylation.通过直接反馈磷酸化对Raf-1进行调控。
Mol Cell. 2005 Jan 21;17(2):215-24. doi: 10.1016/j.molcel.2004.11.055.
Zotero 插件